The two companies will also evaluate the potential use of the assay in combination with pioglitazone in high-risk older adults with normal cognition.
The TOMM40 biomarker, which was discovered by the team at Zinfandel Pharmaceuticals, is being developed to detect individuals at high risk of developing Alzheimer’s disease within the subsequent five years.
Under the agreement, the Takeda and Zinfandel will prospectively validate the TOMM40 biomarker as a test of individual risk.
Zinfandel will receive from Takeda an upfront payment of $9m and subsequent payments of up to $78m based on development milestones, while Takeda will obtain an exclusive license for TOMM40 biomarker assay.
